Early Access Program for ALXN1840 in Patients with Wilson Disease

Study identifier:D9430R00001

ClinicalTrials.gov identifier:NCT05686564

EudraCT identifier:N/A

CTIS identifier:N/A

Other

Official Title

Early Access Program for ALXN1840 in Patients with Wilson Disease

Medical condition

Wilson Disease

Phase

-

Healthy volunteers

-

Study drug

ALXN1840

Sex

All

Actual Enrollment

-

Study type

Expanded Access

Age

3 Years +

Date

Study Start Date: -
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 May 2023 by Alexion Pharmaceuticals, Inc.

Sponsors

Alexion Pharmaceuticals, Inc.

Collaborators

-

Inclusion and exclusion criteria